Hepatitis C: China FDA approves Daklinza and Sunvepra, First all-oral regimen

Bristol-Myers Squibb Company announced Friday that the China Food and Drug Administration (CFDA) has approved a direct-acting antiviral regimen comprised of Daklinza (R) (daclatasvir) and Sunvepra (R)(asunaprevir), for the treatment of treatment-naive or -experienced patients, with or without compensated cirrhosis, infected with genotype 1b chronic hepatitis C virus (HCV). This is China's first all-oral, interferon- ["]

The post Hepatitis C: China FDA approves Daklinza and Sunvepra, First all-oral regimen appeared first on Outbreak News Today.